Anderson J L
University of Utah Medical School, LDS Hospital, Salt Lake City 84143.
Am J Cardiol. 1990 Feb 20;65(8):32D-40D. doi: 10.1016/0002-9149(90)91415-3.
Comparative trials of a new drug with standard antiarrhythmic agents are important for establishing relative efficacy and tolerance. For moricizine, such trials have included comparisons with propranolol, disopyramide and quinidine. Furthermore, the Cardiac Arrhythmia Pilot Study compared moricizine in postinfarction patients with encainide and flecainide. These trials show moricizine to be superior in efficacy to a beta blocker (propranolol) and disopyramide and equivalent to quinidine. Although the class IC drugs (encainide and flecainide) showed somewhat greater efficacy in the Cardiac Arrhythmic Pilot Study, they are now known to increase the risk of mortality in postinfarction patients. Moricizine was also shown to be well tolerated in these trials and associated with fewer discontinuations than propranolol, disopyramide and quinidine. Thus, moricizine is a promising new agent when profiled against other drugs frequently used for therapy of chronic ventricular arrhythmias.
将一种新药与标准抗心律失常药物进行对比试验，对于确定相对疗效和耐受性很重要。对于莫雷西嗪来说，此类试验包括与普萘洛尔、丙吡胺和奎尼丁的对比。此外，心律失常初步研究比较了心肌梗死后患者使用莫雷西嗪与恩卡尼和氟卡尼的情况。这些试验表明，莫雷西嗪在疗效上优于β受体阻滞剂（普萘洛尔）和丙吡胺，与奎尼丁相当。尽管IC类药物（恩卡尼和氟卡尼）在心律失常初步研究中显示出稍高的疗效，但现在已知它们会增加心肌梗死后患者的死亡风险。在这些试验中还表明，莫雷西嗪耐受性良好，与普萘洛尔、丙吡胺和奎尼丁相比，停药情况较少。因此，与常用于治疗慢性室性心律失常的其他药物相比，莫雷西嗪是一种有前景的新药。
